Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Year 2016, Volume: 43 Issue: 1, - , 01.03.2016

Durmuş Çetin Ebubekir Gündeş Ulaş Aday Hüseyin Çiyiltepe Kamuran Değer Mustafa Duman

https://doi.org/10.5798/diclemedj.0921.2016.01.0661

Cited By: 1

Abstract

Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery.
Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer

Keywords

Bevacizumab , ince barsak perforasyonu , metastatik kolorektal kanser

References

• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779- 1802.
• Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006;4:808-821.
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
• Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354-3360.
• Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
• Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab.
• Am J Health Syst Pharm 2009; 66:999-1013.
• Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-869.
• Badgwell BD, Camp ER, Feig B, et al. Management of evacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-582.
• Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180.
• Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008;40:33-35.